AstraZeneca Questions Reliability Of Crestor Adverse Event Reports

A Public Citizen petition seeking withdrawal of rosuvastatin is “based on inappropriate and misleading interpretations of selective and incomplete data,” CEO McKillop says. AstraZeneca asserts Crestor’s adverse event profile is similar to other statins.